Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) on Monday, soared 1.81% from the previous trading day, before settling in for the closing price of $1.66. Within the past 52 weeks, LXRX’s price has moved between $0.92 and $3.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 186.21%. The company achieved an average annual earnings per share of 14.47%. With a float of $349.01 million, this company’s outstanding shares have now reached $361.49 million.
The extent of productivity of a business whose workforce counts for 285 workers is very important to gauge. In terms of profitability, gross margin is 80.66%, operating margin of -5412.11%, and the pretax margin is -5509.34%.
Lexicon Pharmaceuticals Inc (LXRX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Lexicon Pharmaceuticals Inc is 3.45%, while institutional ownership is 76.85%. The most recent insider transaction that took place on Aug 15 ’24, was worth 480,000. Before that another transaction happened on Nov 16 ’23, when Company’s Chief Executive Officer bought 90,000 for $1.05, making the entire transaction worth $94,797. This insider now owns 914,359 shares in total.
Lexicon Pharmaceuticals Inc (LXRX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 14.47% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
Lexicon Pharmaceuticals Inc (LXRX) is currently performing well based on its current performance indicators. A quick ratio of 11.49 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 167.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.77, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
The latest stats from [Lexicon Pharmaceuticals Inc, LXRX] show that its last 5-days average volume of 2.47 million was inferior to 3.61 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 56.07%. Additionally, its Average True Range was 0.15.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 21.21%, which indicates a significant increase from 20.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 116.85% in the past 14 days, which was higher than the 81.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8463, while its 200-day Moving Average is $1.7979. Now, the first resistance to watch is $1.7200. This is followed by the second major resistance level at $1.7500. The third major resistance level sits at $1.7900. If the price goes on to break the first support level at $1.6500, it is likely to go to the next support level at $1.6100. The third support level lies at $1.5800 if the price breaches the second support level.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
Market capitalization of the company is 610.92 million based on 246,237K outstanding shares. Right now, sales total 1,200 K and income totals -177,120 K. The company made 1,650 K in profit during its latest quarter, and -53,430 K in sales during its previous quarter.
